“The fact that this study showed a significant difference in its primary end point and the objective response rate suggests that FOLFIRINOX should be considered as a standard of care,” researchers wrote.
Children with ALL who were overweight or obese at 2 or more time points had an increased risk of relapse and death.
Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.
Adding inavolisib to palbociclib and fulvestrant improves OS in patients with PIK3CA-mutant, HR-positive, HER2-negative, advanced breast cancer.
We are introducing a new way to deliver the most relevant information you need for your patients on the topics that matter most to your…
“The results of our study suggest a concerning pattern in cancer center advertising, particularly among top-ranked institutions,” researchers wrote.
Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.
Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.
T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.
Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.
Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.
